Craft

Jazz Pharmaceuticals

Stock Price

$114

2024-04-09

Market Capitalization

$7.1 B

2024-04-09

Revenue

$3.8 B

FY, 2023

Jazz Pharmaceuticals Summary

Company Summary

Overview
Jazz Pharmaceuticals is an international biopharmaceutical company, focused on identifying, developing, and commercializing products for neurology and psychiatry. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning.
Type
Public
Status
Active
Founded
2003
HQ
Dublin, IE | view all locations
Website
https://www.jazzpharma.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • George Eliades

    George Eliades, Senior Vice President, Corporate Development and Chief Transformation Officer

  • Renée Galá

    Renée Galá, Executive Vice President and Chief Financial Officer

  • Robert Iannone

    Robert Iannone, Executive Vice President, Global Head of Research and Development

  • Paul L. Berns, Director

    LocationsView all

    14 locations detected

    • Dublin, County Dublin HQ

      Ireland

      Waterloo Exchange, Waterloo Road

    • Carlsbad, CA

      United States

      5750 Fleet St #200

    • Palo Alto, CA

      United States

      3170 Porter Dr

    • Philadelphia, PA

      United States

      2005 Market St #2100

    • Mississauga, ON

      Canada

      602-4080 Confederation Pkwy

    • Vancouver, BC

      Canada

      250-887 Great Northern Way

    and 8 others

    Jazz Pharmaceuticals Financials

    Summary Financials

    Revenue (FY, 2023)
    $3.8B
    Net income (FY, 2023)
    $414.8M
    Cash (FY, 2023)
    $1.5B
    EBIT (FY, 2023)
    $578.6M
    Enterprise value
    $11.3B

    Footer menu